PedAM
Pediatric Disease Annotations & Medicines
| Disease | thrombocytosis |
| Phenotype | C0027022|myeloproliferative disorder |
| Sentences | 5 |
| PubMedID- 25807961 | Controversies still exist regarding definition of the thrombotic risks in ph- (bcr/abl1-) myeloproliferative disorders with thrombocythemia (mpd-t). |
| PubMedID- 20586925 | Background: anagrelide is a selective inhibitor of megakaryocytopoiesis used to treat thrombocytosis in patients with chronic myeloproliferative disorders. |
| PubMedID- 19958208 | Conclusions: among all indices, the pdw has been receiving attention due to its usefulness for distinguishing between reactive thrombocytosis and thrombocytosis associated with myeloproliferative disorder. |
| PubMedID- 21312258 | myeloproliferative disorders may present with thrombocytosis and/or leukocytosis with symptoms ranging from minor to life-threatening. |
| PubMedID- 24744668 | In patients with thrombocythemia associated with chronic myeloproliferative disorders, increased hematocrit and viscosity aggravate the platelet-mediated microvascular ischemic and thrombotic syndrome of thrombocythemia to major arterial and venous thrombotic complications. |
Page: 1